Article Open access 15 December 2021 Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours Article Open access 18 November 2021 Back...
Treatment with JMT101 alone from 1 to 200ug/ml had minimal effect on cell viability (Supplementary Fig 1a). While adding JMT101 (10ug/ml) to afatinib or osimertinib significantly shift the dose-response curves to the left and demonstrated potent antiproliferative effects (Supplementary Fig 1b)....
Potential cytochrome P-450 (CYP) drug-drug interactions in adults with metastatic solid tumors and their effect on eligibility for Phase I clinical trials were characterized.This study included adult patients with metastatic solid tumors seen by a medical oncologist from January 2008 through July 2011...
CLINICAL trialsPROGRESSION-free survivalANTIGEN presentationIntroduction: Rituximab (R) as a single agent is effective in indolent B‐NHL (iB‐NHL), but response rates and durability fall in relapsed/refractory (r/r) disease. Resistance is in part due to variable complement activation. Imprime PGG...
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587–97. Article CAS PubMed PubMed Central Google Scholar Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, ...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/...
No additional dose limiting toxicities (DLT) were observed in Cohort A since the initial Phase 1a dose escalation.Clinical activity for IMA203 TCR-T monotherapy in Phase 1b Cohort A: IMA203 monotherapy demonstrates a high rate of deep objective responses with ongoing durabilit...
Prescribing information:Consult the full prescribing information for BIKTARVY for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments. Enzymes/transporters:Drugs that induce ...
1A-HBV indicates single-antigen hepatitis B virus vaccine; 3A-HBV, 3-antigen HBV; AE, adverse event; and SAE, serious AE. aIndividuals may have multiple reasons for exclusion. Figure 2. Seroprotection Rates and Serum Hepatitis B Surface Antibody (Anti-HB) Concentrations in Pooled 3-Antigen ...
(Fig.1a). Deficiencies in PCC lead to an accumulation of toxic metabolites, including propionyl-CoA and organic acids, such as 2-methylcitrate (2-MC) and 3-hydroxypropionate (3-HP)2,3. The birth prevalence of PA varies by country, affecting approximately 1 in 100,000 to 150,000 ...